Invesco’s Contineum Therapeutics CTNM Stock Holding History

Invesco’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-10,771	Closed	-$190K	–	3907
2024 Q2	$190K	Buy	+10,771	New	+$173K	﹤0.01%	3635

Other funds holding CTNM

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco's CTNM Position: Q3 2024 in Review

Invesco sold out of Contineum Therapeutics (CTNM) in Q3 2024, closing a stake of 10,771 shares — an estimated $190K sold.

Invesco first reported a position in CTNM in Q2 2024 and held it in 1 quarter. The position peaked at $190K in Q2 2024. 52 funds tracked by Wall St. Rank hold CTNM as of Q3 2024.

Invesco reported no remaining Contineum Therapeutics position as of Q3 2024 after selling out during the quarter.
Invesco sold 10,771 Contineum Therapeutics shares in Q3 2024, an estimated $190K.
Invesco first reported a position in Contineum Therapeutics in Q2 2024 and held it in 1 quarter.
Invesco's Contineum Therapeutics position peaked at $190K in Q2 2024.
52 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2024.

Based on Invesco's 13F filing for Q3 2024, filed 12 Nov 2024.